Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARIZ-PRDM1-siRNA
- Development stage
- Preclinical
- Lead developer
- ARIZ Precision Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
ARIZ Precision Medicine-PRDM1-siRNA-Colon Cancer is an experimental RNA interference (RNAi) therapeutic being developed by ARIZ Precision Medicine for the treatment of colon cancer. The drug consists of a small interfering RNA (siRNA) designed to knock down the expression of PRDM1 (PR domain zinc finger protein 1, also known as BLIMP-1), an epigenetic regulator and transcription factor that plays a critical role in cancer development and progression. The siRNA is delivered using ARIZ's proprietary Targeted Drug Delivery System (T-DDS), which utilizes nanoparticle technology to specifically target cancer cells. The program is currently in the early stages of development, ranging from target identification to proof-of-principle in the T-DDS platform.
- Other names
- PRDM1-siRNA (Colon Cancer)ARIZ Colon Cancer ProgramARIZ Precision Medicine-PRDM1-siRNA-Colon Cancer
02
Targets
PRDM1 (PR domain zinc finger protein 1)
Beyond the preview
Go deeper on ARIZ-PRDM1-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARIZ-PRDM1-siRNA.